Amicus Therapeutics filings document the former public company’s rare-disease biotechnology business, common stock registration, operating results, governance matters, shareholder voting disclosures, material agreements, risk factors, clinical or regulatory updates, and capital-structure information. The filing record includes Form 8-K reports for quarterly results, corporate updates, and material events tied to its business and securities.
Later filings document Amicus Therapeutics’ completed merger, its survival as a wholly owned subsidiary of BioMarin Pharmaceutical Inc., the removal of its common stock from Nasdaq listing through Form 25, and the termination or suspension of Exchange Act reporting obligations through Form 15. These documents record the company’s transition from a Nasdaq-listed issuer to a subsidiary within BioMarin.
Amicus Therapeutics has completed its merger with BioMarin Pharmaceutical, becoming a wholly owned subsidiary of BioMarin. At closing, each share of Amicus common stock was converted into the right to receive $14.50 in cash per share, without interest and subject to tax withholding.
In connection with the merger, Amicus fully repaid and terminated all commitments under its October 2, 2023 Amicus Credit Agreement and released related guarantees and liens. The company notified Nasdaq of the merger, requested delisting of its common stock, and plans to terminate its SEC reporting obligations after the Form 25 and subsequent Form 15 become effective.
All Amicus directors and executive officers resigned at the merger’s effective time, with the former directors and officers of the merger subsidiary assuming equivalent roles. The company’s certificate of incorporation and bylaws were amended and restated to align with those of the merger subsidiary, reflecting its new status under BioMarin’s control.